We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

On February 3rd, three insiders acquired a total of $94.22 million in Metsera shares at $18 per share during the company’s initial public offering. The company raised $257 million during its IPO ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze ...

Micropolis intends to use the proceeds from the Offering for talent acquisition, marketing and public relations, acquisition of machinery and advanced equipment, R&D specific expenses, contracts & ...

KIRKLAND, Wash., March 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, today announced the pricing of its upsized ...

Kestra Medical Technologies (NASDAQ:KMTS) stock debuts on Nasdaq with a 33% IPO jump. Learn about their growth, cardiac ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...